Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
Rezafungin (Rezzayo) Peptide
Once-weekly echinocandin for candidemia and invasive candidiasis.
What is Rezafungin (Rezzayo)?
Rezafungin (Rezzayo) is a echinocandin · antifungal peptide studied for candidemia and invasive candidiasis. Below is an educational overview of Rezafungin (Rezzayo) peptide benefits, mechanism, common research protocols, dosage references, and known side effects.
Plain-Language Label Highlights
Brand names: Rezzayo
Candidemia and invasive candidiasis in adults with limited treatment options.
A once-weekly IV antifungal (newer echinocandin) — convenient dosing for serious Candida infections.
- •Low potassium
- •Diarrhea
- •Anemia
- •Nausea
- •Headache
- •Infusion reactions
- •Photosensitivity
- •Embryo-fetal toxicity (animal data)
- •Pregnancy (unless benefits outweigh risks)
- •Known echinocandin hypersensitivity
Educational summary of the FDA prescribing information. Not a substitute for the full label or medical advice. Always discuss with a licensed prescriber.
Rezafungin (Rezzayo) Mechanism of Action
Next-generation echinocandin structurally related to anidulafungin with enhanced stability, inhibiting β-(1,3)-D-glucan synthase; long half-life permits once-weekly IV dosing.
Rezafungin (Rezzayo) Research Areas & Benefits
Rezafungin (Rezzayo) Dosage & Common Research Protocols
400 mg IV week 1, then 200 mg IV weekly.
Protocols summarized for educational reference from published research. Not dosing guidance.
Rezafungin (Rezzayo) Studies & Cited Research
ReSTORE trial
Non-inferior to caspofungin for candidemia/invasive candidiasis.
Why we trust this source: Published in a peer-reviewed scientific journal with editorial and reviewer oversight.
Citations are linked to PubMed, Google Scholar, and Crossref searches so you can verify the source independently. All references are reviewed during our editorial passes (last reviewed June 1, 2026).
Rezafungin (Rezzayo) Side Effects & Safety Considerations
- •FDA-approved (2023).
- •Infusion reactions and photosensitivity reported.
Explore more peptides
Educational Information Only — Not Medical Advice
All content on this page is for educational and informational purposes only. It is not medical advice, diagnosis, or treatment. We make no claims that any peptide can diagnose, treat, cure, or prevent any disease. Peptides discussed are not FDA-approved for the indications listed unless explicitly stated otherwise.
Always consult a licensed healthcare provider before beginning any wellness protocol. Statements have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability, eligibility, and pricing may vary.
Ask the Library
Ask anything about peptides — answers come from our curated reference library with citations.